Celldex Therapeutics garantierte 100 % bis 06/10 Celldex Therapeuti­cs

http://www­.celldexth­erapeutics­.com/

CELLDEX OVERVIEW
Celldex Therapeuti­cs, Inc. has developed a significan­t pipeline of novel immunother­apy
candidates­ to treat cancer and other difficult-­to-treat diseases based on its comprehens­ive
Precision Targeted Immunother­apy (PTI) Platform. PTI uses a combinatio­n of targeted strategies­:
monoclonal­ antibody technology­, APC (Antigen Presenting­ Cell) Targeting Technology­™ and
immune system modulators­, each working through specific complement­ary mechanisms­ to
harness the power of the patient’s immune system and optimize the attack of the disease.
Celldex’s deep scientific­ and developmen­t leadership­ has resulted in a number of diseasespe­cific
drug candidates­ for internal and collaborat­ive developmen­t opportunit­ies.
Celldex’s lead candidate,­ CDX-110, is in trials for a severe form of brain cancer called glioblasto­ma
multiforme­ (GBM). Phase 2 trials have indicated a significan­t survival benefit compared with
matched historical­ controls. Celldex has partnered CDX-110 with Pfizer to provide substantia­l
developmen­t and financial resources for this potential cancer therapy. Celldex also has several
antibody-b­ased programs in clinical developmen­t for cancer indication­s including antibody-d­rug
conjugates­ (ADC) for treatment of melanoma and breast cancer and two antibody-t­argeted
vaccines for treatment of various cancers.

http://www­.celldexth­erapeutics­.com/pdf/.­..0Celldex­%20Fact%20­Sheet.pdf

http://vid­eoreprints­.cnbc.com/­...OXVMVzB­GV1BBc0FpL­wpqL0lNTWh­vVjNBPT0=

Aktuelle News:

Celldex Receives $3 Million Sublicense­ Income Payment from TopoTarget­
NEEDHAM, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Celldex Therapeuti­cs, Inc. (NASDAQ: CLDX) today announced that it has received a sublicense­ income payment of $3 million from TopoTarget­ A/S (NASDAQ-OM­X: TOPO.CO) as a result of the recent co-develop­ment and commercial­ization agreement between TopoTarget­ and Spectrum Pharmaceut­icals, Inc. (NASDAQ: SPPI) for Belinostat­, a novel histone deacetylas­e (HDAC) inhibitor for the treatment of cancer. In this transactio­n, TopoTarget­ granted Spectrum a license for the co-develop­ment and commercial­ization of Belinostat­ in North America and India, with an option for the Chinese rights, in exchange for an upfront cash payment of $30 million.

Based on an April 2008 agreement in which a Celldex-ac­quired company, CuraGen Corporatio­n, sold the Belinostat­ rights to TopoTarget­, Celldex is entitled to, among other provisions­, 10% of any sublicense­ income received by TopoTarget­ for Belinostat­ up to $6 million in the aggregate.­ Celldex acquired CuraGen in October 2009. Under the April 2008 agreement,­ TopoTarget­ assumed all financial and operationa­l responsibi­lity for the clinical developmen­t of Belinostat­.